These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34154502)

  • 1. Levels of lymphocyte-associated regulators of complement system CD55 and CD59 are changed in schizophrenia patients.
    Togay A; Togay B; Ozbay Gediz D; Akbaş SH; Köksoy S
    Int J Psychiatry Clin Pract; 2021 Sep; 25(3):277-282. PubMed ID: 34154502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.
    Dammermann W; Schipper P; Ullrich S; Fraedrich K; Schulze Zur Wiesch J; Fründt T; Tiegs G; Lohse A; Lüth S
    PLoS One; 2013; 8(9):e74880. PubMed ID: 24086391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease.
    Mishra N; Mohata M; Narang R; Lakshmy R; Hazarika A; Pandey RM; Das N; Luthra K
    Front Immunol; 2019; 10():2072. PubMed ID: 31555286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus.
    Richaud-Patin Y; Pérez-Romano B; Carrillo-Maravilla E; Rodriguez AB; Simon AJ; Cabiedes J; Jakez-Ocampo J; Llorente L; Ruiz-Argüelles A
    Immunol Lett; 2003 Aug; 88(2):95-9. PubMed ID: 12880676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
    Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
    Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus.
    Li L; Cong B; Yu X; Deng S; Liu M; Wang Y; Wang W; Gao M; Xu Y
    Arch Oral Biol; 2021 Apr; 124():105064. PubMed ID: 33529836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.
    Christmas SE; de la Mata Espinosa CT; Halliday D; Buxton CA; Cummerson JA; Johnson PM
    Immunology; 2006 Dec; 119(4):522-8. PubMed ID: 16999828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
    Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
    APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.
    Li Y; Parks GD
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29693588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.
    Leaderer D; Cashman SM; Kumar-Singh R
    J Gene Med; 2015; 17(6-7):101-15. PubMed ID: 25917932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of membrane complement regulators in neuromyelitis optica.
    Saadoun S; Papadopoulos MC
    Mult Scler; 2015 Nov; 21(13):1644-54. PubMed ID: 25698168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.